Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 28Paclitaxel 24Carboplatin 19Bevacizumab 14Specimen Handling 13Magnetic Resonance Spectroscopy 10Doxorubicin 8Cisplatin 8Biopsy 8olaparib 7lenvatinib 7Taxes 7Letrozole 7Megestrol Acetate 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Medroxyprogesterone Acetate 5Gemcitabine 5trastuzumab deruxtecan 4abemaciclib 4X-Rays 4Trastuzumab 4Tirzepatide 4Progestins 4Oxaliplatin 4Immunoglobulin G 4Fluorouracil 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × STX-478 × 90 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡